172 related articles for article (PubMed ID: 8044831)
21. Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
Rubin M; Bluestone JA; Newell KA; Prokhorova A; Mokyr MB
J Immunol; 1994 Apr; 152(7):3522-9. PubMed ID: 8144932
[TBL] [Abstract][Full Text] [Related]
22. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells.
Sojka DK; La Motte RN; Mokyr MB
Cancer Immunol Immunother; 2000 Apr; 49(1):10-22. PubMed ID: 10782862
[TBL] [Abstract][Full Text] [Related]
23. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Barker E; Mokyr MB
Cancer Immunol Immunother; 1990; 31(3):129-38. PubMed ID: 2337902
[TBL] [Abstract][Full Text] [Related]
24. Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
Bocian RC; Ben-Efraim S; Dray S; Mokyr MB
Cancer Immunol Immunother; 1984; 18(1):41-8. PubMed ID: 6435857
[TBL] [Abstract][Full Text] [Related]
25. Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.
Bartik MM; Baumgartel-Scofield BA; Mokyr MB
Cancer Immunol Immunother; 1991; 34(2):79-89. PubMed ID: 1760820
[TBL] [Abstract][Full Text] [Related]
26. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
Barker E; Mokyr MB
Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
[TBL] [Abstract][Full Text] [Related]
27. The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.
Ben-Efraim S; Shoval S; Ophir R
Cancer Immunol Immunother; 1986; 22(1):43-8. PubMed ID: 2939947
[TBL] [Abstract][Full Text] [Related]
28. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.
Mokyr MB; Kalinichenko T; Gorelik L; Bluestone JA
Cancer Res; 1998 Dec; 58(23):5301-4. PubMed ID: 9850053
[TBL] [Abstract][Full Text] [Related]
29. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
30. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression.
Kalinichenko VV; Mokyr MB; Graf LH; Cohen RL; Chambers DA
J Immunol; 1999 Sep; 163(5):2492-9. PubMed ID: 10452985
[TBL] [Abstract][Full Text] [Related]
31. Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.
Bocian RC; Dray S; Ben-Efraim S; Mokyr MB
Cancer Immunol Immunother; 1985; 20(1):61-8. PubMed ID: 3933817
[TBL] [Abstract][Full Text] [Related]
32. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.
Wise JA; Mokyr MB; Dray S
Cancer Immunol Immunother; 1988; 27(3):191-7. PubMed ID: 3263205
[TBL] [Abstract][Full Text] [Related]
33. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells.
Sojka DK; Donepudi M; Bluestone JA; Mokyr MB
J Immunol; 2000 Jun; 164(12):6230-6. PubMed ID: 10843675
[TBL] [Abstract][Full Text] [Related]
34. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.
Ben-Efraim S; Bocian RC; Mokyr MB; Dray S
Cancer Immunol Immunother; 1983; 15(2):101-7. PubMed ID: 6553510
[TBL] [Abstract][Full Text] [Related]
35. Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression.
Jovasevic VM; Mokyr MB
J Immunol; 2001 Nov; 167(9):4895-901. PubMed ID: 11673494
[TBL] [Abstract][Full Text] [Related]
36. Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.
Mokyr MB; Prokhorova A; Rubin M; Bluestone JA
J Immunol; 1994 Oct; 153(7):3123-34. PubMed ID: 8089490
[TBL] [Abstract][Full Text] [Related]
37. Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors.
Laude M; Russo KL; Mokyr MB; Dray S
Cancer Immunol Immunother; 1993 Jul; 37(2):89-96. PubMed ID: 8319246
[TBL] [Abstract][Full Text] [Related]
38. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
39. Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism.
Mokyr MB; Kalinichenko TV; Gorelik L
Cell Immunol; 1997 Jun; 178(2):152-61. PubMed ID: 9225006
[TBL] [Abstract][Full Text] [Related]
40. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells.
Donepudi M; Jovasevic VM; Raychaudhuri P; Mokyr MB
Cancer Immunol Immunother; 2003 Mar; 52(3):162-70. PubMed ID: 12649745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
